Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$12.07M
Enterprise Value$14.85M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue23.10
Enterprise Value/Gross Profit-112.78
Enterprise Value/Ebitda-2.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved CapitalizationDebt levels have fallen and equity is sizable versus assets, which materially improves liquidity and reduces near-term refinancing pressure. This stronger capitalization lengthens runway for development programs and lowers immediate dilution risk, a durable support for strategic execution.
Insider Alignment & R&D FundingThe chairman's personal share purchases and direct investment into the subsidiary's R&D build align management with shareholders and inject non-dilutive capital into product development. That durable support improves the company's ability to advance pipeline assets and strengthen manufacturing capabilities (cGMP complement).
Strategic International ExpansionRebranding and a stated push into Asia and international markets signals a strategic shift to diversify commercial channels and partnerships. If executed, this broadens the addressable market and reduces concentration risk, offering a lasting avenue to grow revenue beyond the domestic base.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow, worsening in 2025, forces reliance on external financing or insider injections. This ongoing cash burn constrains R&D scale-up and commercialization pacing, increases dilution risk, and is a durable constraint until cash generation turns positive.
Sustained Losses & Weak MarginsThe company has posted recurring operating and net losses with deteriorating margins and a negative gross profit in 2025, indicating worsening unit economics. Such persistent unprofitability undermines long-term viability absent successful commercialization or major cost structure changes.
Small, Volatile Revenue BaseA tiny, unpredictable revenue base that fell sharply in 2025 limits the company's ability to cover fixed costs and makes planning uncertain. This structural volatility increases dependence on external funding and partnerships for sustainable development and commercialization.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $12.07M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Technical Analysis
Ownership Overview
33.15% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
66.62% Public Companies and
Individual Investors